MNOV
$5.88
Medicinova
($.04)
(.68%)
MNOV
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.10)
Revenue:  N/A
Tuesday
Oct 27
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when MNOV reports earnings?
Beat
Meet
Miss

Where is MNOV's stock price going from here?
Up
Flat
Down
Stock chart of MNOV
Analysts
Summary of analysts' recommendations for MNOV
Score
Grade
Pivots
Resistance
$6.46
$6.34
$6.13

$6.01

Support
$5.80
$5.68
$5.47
Tweet
Growth
Description
MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonZoetisBristol-Myers SquibbUltragenyx PharmaceuticalCatalentMerck & Co.